ReviewAsia-Pacific journal of clinical oncology2021
Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
Review in Asia-Pacific journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Rheumatic immune-related adverse effects of immune checkpoint treatment: a retrospective multicentre study.Scientific reports · 2026Observational
- Immune checkpoint inhibitor-related arthritis and oral disorders: shared pathophysiology and clinical implications for rheumatology and oral health.Cancer cell international · 2025Review
- Avidity-Based Capture of PD-L1-Expressing Exosomes via Dendrimer-Peptide Conjugates: A Nanoengineered Platform for Enhanced Prediction of Immunotherapy Response.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Nanomedicine targeting the PD-1/PD-L1 axis in autoimmune diseases: breaking conventional barriers to restore immune tolerance.Journal of nanobiotechnology · 2025Review
- Article
- Immune Checkpoint Inhibitor-Related Aortitis Treated with Nivolumab for Esophageal Squamous Cell Carcinoma.Surgical case reports · 2025Article
- Relapsing polychondritis following PD-1 blockade diagnosed via 18F-FDG PET/CT and improved by steroid administration: a case report and literature review.Frontiers in immunology · 2025Review
- A case report of immune checkpoint inhibitor-related myositis and cholangitis induced by pembrolizumab.Clinical case reports · 2024Article
- Imatinib-induced dermatomyositisFrontiers in immunology · 2024Article
- A case of urticarial vasculitis associated with atezolizumab.JAAD case reports · 2024Article
- Refractory hypokalemia and metabolic acidosis induced by undifferentiated connective tissue disease secondary to immune checkpoint inhibitors: a case report and literature review.Frontiers in oncology · 2024Article
- Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.The oncologist · 2023Article
- Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study.Life (Basel, Switzerland) · 2023Article
- Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update.International journal of molecular sciences · 2023Review
- Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists.International journal of environmental research and public health · 2023Review
- Mucocutaneous adverse events to immune checkpoint inhibitors.Frontiers in allergy · 2023Review
- Construction of an immune-related lncRNA signature pair for predicting oncologic outcomes and the sensitivity of immunosuppressor in treatment of lung adenocarcinoma.Respiratory research · 2022Article
- Cervical Cancer Immunotherapy: Facts and Hopes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Review
- Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Immune checkpoint inhibitors (ICIs) block the major inhibitory pathways in T cells, resulting in an augmented antitumor response. Immune-related adverse events (irAEs) are a new class of side effects caused by ICIs and tend to be more prevalent in patients with preexisting autoantibodies and autoimmune diseases. The rheumatic subset of irAEs mainly includes arthralgia, arthritis, myalgia, myositis, vasculitis, sicca syndrome, scleroderma and systemic lupus erythematosus. The most common classification system for AEs, the Common Terminology Criteria for Adverse Events, is of limited use for irAEs, especially rheumatic irAEs. Therapy with glucocorticoid and temporary or permanent discontinuation of ICIs are the cornerstones of irAE treatment, and can be complemented with immunosuppressants (e.g., methotrexate), biologic agents (e.g., tumor necrosis factor inhibitors and interleukin-6 receptor antagonists), intravenous immunoglobin and plasma exchange. Thus, the evaluation and treatment of rheumatic irAEs require multidisciplinary cooperation among physicians. Here, we review the most prevalent ICI-associated rheumatic irAEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.